Hood River Capital Management LLC Position in Biotelemetry INC (BEAT) Lowered by $4.21 Million as Stock Price Rose

BioTelemetry, Inc. (NASDAQ:BEAT) LogoInvestors sentiment decreased to 1.04 in 2018 Q2. Its down 0.34, from 1.38 in 2018Q1. It dived, as 12 investors sold BEAT shares while 80 reduced holdings. 39 funds opened positions while 57 raised stakes. 29.62 million shares or 0.63% more from 29.44 million shares in 2018Q1 were reported. Virginia Retirement Et Al invested 0.01% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Rice Hall James Assoc Ltd has 1.09% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 669,076 shares. 1832 Asset Mngmt Lp has 800 shares for 0% of their portfolio. State Of Alaska Department Of Revenue owns 10,188 shares for 0.01% of their portfolio. Curbstone Fin Corporation has invested 0.31% in BioTelemetry, Inc. (NASDAQ:BEAT). Fiera Cap Corporation holds 0.02% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 126,185 shares. Great West Life Assurance Can invested in 39,638 shares. Pitcairn Communication reported 0.04% stake. California Pub Employees Retirement holds 0% or 69,869 shares in its portfolio. Minnesota-based Perkins Cap Management has invested 0.48% in BioTelemetry, Inc. (NASDAQ:BEAT). Manufacturers Life Ins The reported 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Hodges Capital has 0.14% invested in BioTelemetry, Inc. (NASDAQ:BEAT). Voya Investment Management Limited Liability reported 12,980 shares. Lyon Street Cap Ltd Limited Liability Company invested in 212,634 shares. Scout stated it has 157,970 shares or 0.16% of all its holdings.

Hood River Capital Management Llc decreased its stake in Biotelemetry Inc (BEAT) by 7.94% based on its latest 2018Q2 regulatory filing with the SEC. Hood River Capital Management Llc sold 95,725 shares as the company’s stock rose 32.47% with the market. The institutional investor held 1.11M shares of the health care company at the end of 2018Q2, valued at $49.94M, down from 1.21M at the end of the previous reported quarter. Hood River Capital Management Llc who had been investing in Biotelemetry Inc for a number of months, seems to be less bullish one the $2.25 billion market cap company. The stock decreased 1.16% or $0.79 during the last trading session, reaching $67.41. About 177,368 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 55.22% since December 6, 2017 and is uptrending. It has outperformed by 39.60% the S&P500.

Hood River Capital Management Llc, which manages about $698.72M and $1.95 billion US Long portfolio, upped its stake in Globant Sa (NYSE:GLOB) by 188,204 shares to 610,394 shares, valued at $34.66 million in 2018Q2, according to the filing. It also increased its holding in Penn National Gaming Inc (NASDAQ:PENN) by 730,261 shares in the quarter, for a total of 730,749 shares, and has risen its stake in Xcerra Corp (NASDAQ:XCRA).

Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on February, 28. They expect $0.41 earnings per share, up 28.13 % or $0.09 from last year’s $0.32 per share. BEAT’s profit will be $13.65 million for 41.10 P/E if the $0.41 EPS becomes a reality. After $0.53 actual earnings per share reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts -22.64 % negative EPS growth.

More notable recent BioTelemetry, Inc. (NASDAQ:BEAT) news were published by: Nasdaq.com which released: “GameStop (GME) Q3 Earnings Beat, Stock Down on View Cut – Nasdaq” on November 30, 2018, also Nasdaq.com with their article: “Viacom (VIAB) Q4 Earnings Beat Estimates, Revenues Up Y/Y – Nasdaq” published on November 16, 2018, Nasdaq.com published: “YELP Stock Nosedives on Q3 Revenue Miss, Earnings Beat – Nasdaq” on November 08, 2018. More interesting news about BioTelemetry, Inc. (NASDAQ:BEAT) were released by: Nasdaq.com and their article: “Here’s What to Expect from Lululemon’s (LULU) Q3 Earnings – Nasdaq” published on December 05, 2018 as well as Nasdaq.com‘s news article titled: “Has BioTelemetry (BEAT) Outpaced Other Medical Stocks This Year? – Nasdaq” with publication date: November 15, 2018.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 3 analyst reports since June 20, 2018 according to SRatingsIntel. As per Wednesday, October 31, the company rating was maintained by Raymond James. Raymond James maintained the shares of BEAT in report on Friday, September 14 with “Outperform” rating.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.